Your browser is no longer supported. Please, upgrade your browser.
Settings
MNKD MannKind Corporation daily Stock Chart
MNKD [NASD]
MannKind Corporation
Index- P/E- EPS (ttm)-0.80 Insider Own0.40% Shs Outstand159.61M Perf Week-5.98%
Market Cap276.13M Forward P/E- EPS next Y-0.66 Insider Trans3.53% Shs Float145.98M Perf Month-13.07%
Income-110.00M PEG- EPS next Q-0.17 Inst Own23.40% Short Float29.77% Perf Quarter55.86%
Sales16.40M P/S16.84 EPS this Y-182.50% Inst Trans-5.46% Short Ratio8.79 Perf Half Y-11.28%
Book/sh-1.34 P/B- EPS next Y- ROA-169.50% Target Price4.00 Perf Year-46.93%
Cash/sh0.07 P/C26.55 EPS next 5Y26.80% ROE50.60% 52W Range0.98 - 4.05 Perf YTD-25.43%
Dividend- P/FCF- EPS past 5Y24.80% ROI189.70% 52W High-57.28% Beta2.13
Dividend %- Quick Ratio0.30 Sales past 5Y220.00% Gross Margin-18.80% 52W Low76.51% ATR0.12
Employees250 Current Ratio0.30 Sales Q/Q125.00% Oper. Margin- RSI (14)43.82 Volatility4.53% 6.28%
OptionableYes Debt/Eq- EPS Q/Q49.90% Profit Margin- Rel Volume0.37 Prev Close1.80
ShortableYes LT Debt/Eq- EarningsNov 01 BMO Payout- Avg Volume4.94M Price1.73
Recom2.00 SMA20-4.74% SMA50-3.47% SMA200-9.69% Volume1,823,886 Change-3.89%
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Aug-11-17Initiated Maxim Group Buy $4
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Apr-16-15Reiterated RBC Capital Mkts Outperform $13 → $10
Aug-12-14Reiterated RBC Capital Mkts Outperform $16 → $13
Jul-01-14Downgrade MLV & Co Buy → Hold $11
Jun-30-14Reiterated Brinson Patrick Market Outperform $12 → $15
Jun-13-14Initiated RBC Capital Mkts Outperform $16
Apr-02-14Reiterated MLV & Co Buy $9 → $11
Nov-16-18 05:48PM  Edited Transcript of MNKD earnings conference call or presentation 1-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-01-18 09:33AM  MannKind: 3Q Earnings Snapshot Associated Press
08:00AM  MannKind Corporation Reports 2018 Third Quarter Financial Results GlobeNewswire
Oct-31-18 02:46PM  United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-25-18 05:00PM  MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018 GlobeNewswire
Oct-24-18 07:20AM  Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-17-18 08:00AM  Todays Research Reports on Stocks to Watch: Altimmune and MannKind ACCESSWIRE
Oct-16-18 05:22PM  Why MannKind Corp. Soared 16.4% Tuesday Motley Fool +16.36%
06:00AM  United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement PR Newswire
06:00AM  United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement GlobeNewswire
Oct-15-18 09:00AM  Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity GlobeNewswire
Oct-11-18 09:51AM  Here's What Sent MannKind Corporation Soaring 66.4% in September Motley Fool -8.98%
Oct-04-18 09:00AM  MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes GlobeNewswire
Oct-03-18 09:00AM  MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes GlobeNewswire +7.14%
Sep-27-18 02:25PM  MannKind Stock History Motley Fool
Sep-24-18 09:00AM  MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients GlobeNewswire +10.34%
Sep-19-18 04:42AM  Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Sep-13-18 09:00AM  Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics GlobeNewswire
Sep-10-18 08:54AM  Implied Volatility Surging for MannKind (MNKD) Stock Options Zacks +10.67%
08:05AM  Mannkind Afrezza Sales Have Doubled and Treprostinil is Getting Some Traction ACCESSWIRE
Sep-08-18 07:50PM  Is MannKind Corporation Stock a Buy? Motley Fool
07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-06-18 03:02PM  A New Deal Moves MannKind Back From the Brink Motley Fool -6.85%
08:52AM  The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals Zacks
Sep-05-18 04:56PM  New Development Partnership Could Pay Off Big for MannKind Stock InvestorPlace +5.29%
04:30PM  Why Cronos Group, MannKind, and Vera Bradley Jumped Today Motley Fool
11:12AM  MannKind Stock Up on Licensing Deal With United Therapeutics Zacks
10:30AM  The Probable Reason Why MannKind Corporation Is Rallying Again Motley Fool
09:39AM  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars Zacks
Sep-04-18 11:27AM  Why MannKind Stock Is Skyrocketing Today InvestorPlace +89.09%
10:06AM  Why MannKind Corporation Stock Is Skyrocketing Today Motley Fool
09:30AM  3 Stocks to Watch As The Healthcare Sector Heats Up ACCESSWIRE
09:19AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:54AM  United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery American City Business Journals
Aug-29-18 09:00AM  MannKind Corporation to Present at Upcoming Conferences GlobeNewswire
Aug-28-18 07:30AM  Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-23-18 02:31PM  Los Angeles stocks that are driving Wall Street's latest bull run American City Business Journals
Aug-09-18 08:35AM  Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? Zacks
Aug-06-18 04:30PM  Why MannKind Corporation Stock Is Tanking Again Today Motley Fool -12.17%
10:24AM  MannKind Stock Is One Step Away From Obliteration InvestorPlace
Aug-03-18 01:34PM  Can MannKind Corporation Avert Bankruptcy? Motley Fool -23.33%
08:00AM  Today's Research Reports on Trending Tickers: Tesaro and MannKind ACCESSWIRE
Aug-02-18 06:25PM  MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates Zacks
05:40PM  MannKind Corporation (MNKD) Stock Slides Despite Q2 Revenue Growth InvestorPlace
05:20PM  MannKind: 2Q Earnings Snapshot Associated Press
04:00PM  MannKind Corporation Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET GlobeNewswire
Jul-27-18 09:37AM  MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza® GlobeNewswire
09:00AM  MannKind Corporation to Hold 2018 Second Quarter Financial Results Conference Call on August 2, 2018 GlobeNewswire
Jul-21-18 08:25AM  Should Biotech Investors Fear Dilution? Motley Fool
Jul-16-18 07:05AM  Free Technical Research on Marinus Pharma and Three More Biotech Equities ACCESSWIRE
Jun-29-18 08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within MannKind, Healthcare Services Group, Cadence, Superior Energy Services, National Presto Industries, and New Media Investment Group New Research Emphasizes Economic Growth GlobeNewswire
Jun-25-18 09:00AM  MannKind Set to Join Russell 3000® Index GlobeNewswire
08:35AM  Implied Volatility Surging for MannKind Corporation (MNKD) Stock Options Zacks
08:00AM  Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions GlobeNewswire
Jun-23-18 10:00AM  MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions GlobeNewswire
Jun-20-18 04:01PM  MannKind to Host Institutional Investor and Analyst Meeting GlobeNewswire
Jun-07-18 09:00AM  MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase GlobeNewswire
Jun-05-18 04:30PM  MannKind Establishes Market Price Stock Purchase Plan GlobeNewswire
May-17-18 08:00AM  Detailed Research: Economic Perspectives on Churchill Downs, Nordic American Tankers, News Corporation, Aduro Biotech, MannKind, and Crane What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-16-18 08:50AM  Is the Options Market Predicting a Spike in MannKind (MNKD) Stock? Zacks
May-10-18 11:57PM  Edited Transcript of MNKD earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents
09:44AM  Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results Benzinga
06:30AM  MannKind Q1 Results: The Good, the Bad, and the Ugly Motley Fool
May-09-18 04:54PM  MannKind: 1Q Earnings Snapshot Associated Press
04:01PM  MannKind Corporation Reports 2018 First Quarter Financial Results GlobeNewswire
09:00AM  MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India GlobeNewswire
May-08-18 07:28AM  Why MannKind Corporation Stock Broke Down in April Motley Fool
May-02-18 09:00AM  MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018 GlobeNewswire
Apr-28-18 07:06AM  Who Are The Top Investors In MannKind Corporation (NASDAQ:MNKD)? Simply Wall St.
Apr-25-18 04:30PM  FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary GlobeNewswire
08:46AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Apr-13-18 08:19AM  MannKind (MNKD) Enters Oversold Territory Zacks
Apr-09-18 04:10PM  MannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering GlobeNewswire -5.59%
09:00AM  Why MannKind Corporation Stock Sank Last Month Motley Fool
08:41AM  Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? Zacks
Apr-06-18 08:27AM  Here's Why MannKind Corporation Stock Is Tanking Today Motley Fool -24.79%
07:49AM  MannKind's stock sinks after direct stock offering MarketWatch
01:58AM  MannKind Announces $28.0 Million Registered Direct Offering GlobeNewswire
Mar-19-18 08:00AM  MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-16-18 08:41AM  Options Traders Expect Huge Moves in MannKind (MNKD) Stock Zacks
Mar-14-18 08:00AM  MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-13-18 08:00AM  MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Associations 78th Scientific Sessions GlobeNewswire
Mar-12-18 08:08AM  MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million GlobeNewswire
Mar-09-18 07:50AM  Research Report Identifies Neogen, AgroFresh Solutions, Ocean Rig UDW, Superior Energy Services, root9B Holdings, and MannKind with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-08-18 01:00PM  Could MannKind Corporation Be a Millionaire-Maker Stock? Motley Fool
Mar-02-18 10:11PM  Edited Transcript of MNKD earnings conference call or presentation 27-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-01-18 05:41PM  How Four Managers Outperformed In A Volatile Down Month Forbes
04:01PM  MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension GlobeNewswire
Feb-28-18 09:18AM  3 Bright Spots in MannKind Corporation's Q4 Update Motley Fool -7.28%
Feb-27-18 05:37PM  MannKind reports 4Q loss Associated Press
04:01PM  MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-23-18 08:00AM  MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018 GlobeNewswire
Feb-13-18 08:30AM  Todays Research Reports on Trending Tickers: Dare Bioscience and MannKind ACCESSWIRE +10.62%
Feb-06-18 08:35AM  MannKind Corporation Appoints Dr. David Kendall as Chief Medical Officer SmarterAnalyst
08:00AM  David Kendall Joins MannKind as Chief Medical Officer GlobeNewswire
Jan-29-18 04:52PM  Here's Why MannKind Briefly Spiked Today Motley Fool
Jan-26-18 01:13PM  Nate Pile Sells Some Nvidia, Buys More MannKind, Apple, And Celgene Forbes -26.58%
12:09PM  Why MannKind Corporation Stock Is Falling Back to Earth Today Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: MannKind Corporation and Pacific Biosciences of California ACCESSWIRE
Jan-25-18 01:40PM  The Most Likely Reason Why MannKind Corporation Skyrocketed Higher Today Motley Fool +41.26%
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tross Stuart ACorp VP, Chief People OfficerAug 02Buy1.315,0006,55062,960Aug 06 07:21 PM
McCauley PatrickChief Commercial OfficerAug 02Buy1.315,0006,55031,041Aug 06 07:19 PM
Barton CourtneyChief Compliance OfficerAug 02Buy1.315,0006,5507,000Aug 06 07:17 PM
Castagna MichaelChief Executive OfficerAug 02Buy1.315,0006,55068,157Aug 06 07:16 PM
Binder Steven B.Chief Financial OfficerAug 02Buy1.311,7602,3061,760Aug 06 07:17 PM
Tross Stuart ACorp VP, Chief People OfficerDec 21Buy2.5239,840100,39759,840Dec 21 09:36 PM
Castagna MichaelChief Executive OfficerDec 20Buy2.281,5003,4201,500Dec 20 04:53 PM
Castagna MichaelChief Executive OfficerDec 20Buy2.296,50014,87135,532Dec 20 04:53 PM